Screening sperm donors for autism? As an autistic person, I know that’s the road to eugenics
By Ari Ne'eman,
The Guardian
| 12. 30. 2015
[cites CGS]
Untitled Document
Britain’s largest sperm bank has a policy of turning away autistic donors and those diagnosed with other neurological disabilities, such as attention deficit hyperactivity disorder [ADHD], dyslexia and obsessive compulsive disorder.
The London Sperm Bank’s policies are deeply concerning. But to those of us who have been monitoring the ways in which genetic knowledge is being misused across the globe, they are not surprising. In egg donations (as in sperm donations) similar genetic screening of a diagnosis and a family history of autism, dyslexia and obsessive compulsive disorder is not uncommon. There is considerable evidence to support that these are all conditions with strong genetic components.
In the US, where sperm banks are only very lightly regulated, recipients may select for everything from preferred pets and hobbies to astrological sign. In Israel, sperm banks have been fielding a large number of requests for sperm from members of the military, particularly combat soldiers. As early as the 1980s, unsuccessful efforts were made in California to populate a sperm bank entirely with deposits from Nobel prizewinners...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...